CH
CHRS icon

Canton Hathaway’s Coherus Oncology CHRS Stock Holding History

Canton Hathaway’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$81.5K Buy
+58,230
New +$95.1K 0.02% 169

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Canton Hathaway's CHRS Position: Q2 2026 in Review

Canton Hathaway opened a new position in Coherus Oncology (CHRS) in Q2 2026: 58,230 shares worth $81.5K. The stake represents 0.02% of the portfolio and ranks #169 among its holdings.

147 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Canton Hathaway held 58,230 shares of Coherus Oncology worth $81.5K as of Q2 2026.
  • Coherus Oncology was a new Canton Hathaway position in Q2 2026.
  • Coherus Oncology made up 0.02% of Canton Hathaway's portfolio in Q2 2026, its #169 holding.
  • 147 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Canton Hathaway's 13F filing for Q2 2026, filed 6 Aug 2026.